Efficacy of OnabotulinumtoxinA in Migraine

PHASE2CompletedINTERVENTIONAL
Enrollment

32

Participants

Timeline

Start Date

March 13, 2018

Primary Completion Date

May 31, 2020

Study Completion Date

May 31, 2020

Conditions
Migraine
Interventions
DRUG

OnabotulinumtoxinA

BOTOX contains onabotulinumtoxinA, an acetylcholine release inhibitor and a neuromuscular blocking agent available in the lyophilized form of purified clostridium botulinum toxin type A, suitable for injection, for intramuscular, intradetrusor, or intradermal use. The recommended dilution is 100 Units/2 mL, with a final concentration of 5 Units per 0.1 mL. The recommended dose for treating chronic migraine is 155 Units administered intramuscularly using a sterile 30-gauge, needle as 0.1 mL (5 Units) injections per each site.

Trial Locations (1)

27100

Headache Science Center, Pavia

All Listed Sponsors
lead

"IRCCS National Neurological Institute C. Mondino Foundation"

OTHER

NCT04578782 - Efficacy of OnabotulinumtoxinA in Migraine | Biotech Hunter | Biotech Hunter